Diabetic conditions promote drug coating degradation but prevent endothelial coverage after stenting
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Coronary Interventions and Diagnostics · Angiogenesis and VEGF in Cancer · Cell Adhesion Molecules Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (54)
Show source-provided references
1. Epidemiology in diabetes mellitus and cardiovascular disease10.1097/XCE.0000000000000116 ↗
2. Microvascular complications of type 2 diabetes mellitus10.2174/1570161117666190502103733 ↗
3. Mechanisms of drug-eluting stent restenosis10.1007/s12928-020-00734-7 ↗
4. Drug-eluting stent thrombosis: current and future perspectives10.1007/s12928-021-00754-x ↗
5. Targeting smooth muscle cell phenotypic switching in vascular disease10.1016/j.jvssci.2021.04.001 ↗
6. Drug-eluting stent specifically designed to target vascular smooth muscle cell phenotypic modulation attenuated restenosis through the YAP pathway10.1152/ajpheart.00089.2019 ↗
7. Persistent endothelial dysfunction after drug-eluting stents: another continuing cost of reducing restenosis10.1016/j.jcin.2007.10.003 ↗
8. Functionally Incomplete Re-Endothelialization of Stents and Neoatherosclerosis10.1016/j.jcin.2017.08.031 ↗
9. Restoring endothelial function: shedding light on cardiovascular stent development10.1039/D3BM00390F ↗
10. Long-term cardiovascular outcomes of biodegradable polymer drug eluting stents in patients with diabetes versus non-diabetes mellitus: a meta-analysis10.1186/s12933-023-01962-w ↗
11. Early and late stent thrombosis in patients with versus without diabetes mellitus following percutaneous coronary intervention with drug-eluting stents: a systematic review and meta-analysis10.1007/s40256-018-0295-y ↗
12. Diabetes mellitus is independently associated with early stent thrombosis in patients undergoing drug eluting stent implantation: analysis from the Victorian cardiac outcomes registry
13. Coronary stent thrombosis- predictors and prevention
14. Drug-eluting stent outcomes in diabetes10.1586/14779072.2014.853615 ↗
15. Pathogenesis and clinical significance of in-stent restenosis in patients with diabetes10.3390/ijerph182211970 ↗
16. Diabetes and restenosis10.1186/s12933-022-01460-5 ↗
17. Corroded iron stent increases fibrin deposition and promotes endothelialization after stenting10.1002/btm2.10469 ↗
18. Insulin resistance, hyperleptinemia and endothelial dysfunction in coronary restenosis10.1016/j.coph.2004.10.004 ↗
19. Hyperglycemia-induced oxidative stress and its role in diabetes mellitus related cardiovascular diseases10.2174/1381612811319320005 ↗
20. FBXW7 alleviates hyperglycemia-induced endothelial oxidative stress injury via ROS and PARP inhibition10.1016/j.redox.2022.102530 ↗
21. Tissue characteristics of neointima in late restenosis: integrated backscatter intravascular ultrasound analysis for in-stent restenosis10.1007/s00380-016-0903-1 ↗
22. Iron corroded granules inhibiting vascular smooth muscle cell proliferation
23. Effects of rapamycin and tacrolimus on mature endothelial cells and endothelial progenitor cells
24. Rapamycin impairs endothelial cell function in human internal thoracic arteries10.1186/s40001-015-0150-4 ↗
25. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells10.1161/01.RES.76.3.412 ↗
26. Rapamycin inhibits vascular smooth muscle cell migration10.1172/JCI119038 ↗
27. The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells10.1074/jbc.M203298200 ↗
28. Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design10.1161/CIRCULATIONAHA.105.569129 ↗
29. Endothelial dysfunction and coronary vasoreactivity - a review of the history, physiology, diagnostic techniques, and clinical relevance10.2174/1573403X16666200618161942 ↗
30. Rapamycin activates TGF receptor independently of its ligand: implications for endothelial dysfunction10.1042/CS20171457 ↗
31. Endothelial cell control of thrombosis10.1186/s12872-015-0124-z ↗
32. Endothelial cells and coagulation10.1007/s00441-021-03471-2 ↗
33. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications10.1161/CIRCULATIONAHA.106.675934 ↗
34. Drug-eluting stent thrombosis10.1177/1753944708096280 ↗
35. Reactive oxygen species (ROS) in macrophage activation and function in diabetes10.1016/j.imbio.2018.11.010 ↗
36. Reactive oxygen species: drivers of physiological and pathological processes10.2147/JIR.S275595 ↗
37. In vivo real-time dynamics of ATP and ROS production in axonal mitochondria show decoupling in mouse models of peripheral neuropathies10.1186/s40478-019-0740-4 ↗
38. Reactive oxygen species - sources, functions, oxidative damage
39. Superoxide dismutases: dual roles in controlling ROS damage and regulating ROS signaling10.1083/jcb.201708007 ↗
40. Targeting PCNA with peptide mimetics for therapeutic purposes10.1002/cbic.201900275 ↗
41. Quantification of epithelial cell proliferation, cell dynamics, and cell kinetics in vivo10.1002/wdev.274 ↗
42. Apoptosis and proliferating cell nuclear antigen in lupus nephritis (class IV) and membranoproliferative glomerulonephritis10.1081/JDI-42724 ↗
43. Proliferating cell nuclear antigen expression in normal, regenerative, and neoplastic liver: a fine-needle aspiration cytology and biopsy study10.1016/0046-8177(93)90141-3 ↗
44. Proliferating cell nuclear antigen (PCNA): a key factor in DNA replication and cell cycle regulation10.1093/aob/mcq243 ↗
45. Cell cycle, CDKs and cancer: a changing paradigm10.1038/nrc2602 ↗
46. Cyclin B1/CDK1-regulated mitochondrial bioenergetics in cell cycle progression and tumor resistance10.1016/j.canlet.2018.11.019 ↗
47. Cyclin-dependent kinase-1: linking apoptosis to cell cycle and mitotic catastrophe10.1038/sj.cdd.4401130 ↗
48. CDK1 switches mitotic arrest to apoptosis by phosphorylating Bcl-2/Bax family proteins during treatment with microtubule interfering agents10.1002/cbin.10259 ↗
49. A novel drug-eluting stent coated with an integrin-binding cyclic Arg-Gly-Asp peptide inhibits neointimal hyperplasia by recruiting endothelial progenitor cells10.1016/j.jacc.2005.11.081 ↗
50. Benefits and harms of intensive glycemic control in patients with type 2 diabetes10.1136/bmj.l5887 ↗
51. The role of glucose lowering agents on restenosis after percutaneous coronary intervention in patients with diabetes mellitus10.1186/1475-2840-8-41 ↗
52. ICAM-1 deletion delays the repair process in aging diabetic mice10.1016/j.metabol.2020.154412 ↗
53. Diabetes influences the fusion of autophagosomes with lysosomes in SH-SY5Y cells and induces Abeta deposition and cognitive dysfunction in STZ-induced diabetic rats10.1016/j.bbr.2023.114286 ↗
54. Stent material surface and glucose activate mononuclear cells of control, type 1 and type 2 diabetes subjects10.1002/jbm.a.31204 ↗